Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38316002)

  • 1. In persons aged ≥45 y, the mt-sRNA test had 94% sensitivity for colorectal cancer and 46% for advanced adenomas.
    Murff HJ
    Ann Intern Med; 2024 Feb; 177(2):JC23. PubMed ID: 38316002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multitarget Stool RNA Test for Colorectal Cancer Screening.
    Barnell EK; Wurtzler EM; La Rocca J; Fitzgerald T; Petrone J; Hao Y; Kang Y; Holmes FL; Lieberman DA
    JAMA; 2023 Nov; 330(18):1760-1768. PubMed ID: 37870871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of multitarget stool DNA testing in African American patients.
    Cooper GS; Markowitz SD; Chen Z; Tuck M; Willis JE; Berger BM; Brenner DE; Li L
    Cancer; 2018 Oct; 124(19):3876-3880. PubMed ID: 30193399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Review of Multitarget Stool DNA as a Screening Test for Colorectal Cancer.
    Kleinschmidt TK; Clements A; Parker MA; Scarcliff SD
    Am Surg; 2023 Apr; 89(4):603-606. PubMed ID: 34278822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population.
    Bosch LJW; Melotte V; Mongera S; Daenen KLJ; Coupé VMH; van Turenhout ST; Stoop EM; de Wijkerslooth TR; Mulder CJJ; Rausch C; Kuipers EJ; Dekker E; Domanico MJ; Lidgard GP; Berger BM; van Engeland M; Carvalho B; Meijer GA
    Am J Gastroenterol; 2019 Dec; 114(12):1909-1918. PubMed ID: 31764091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
    Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
    Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of multitarget stool DNA testing for colorectal cancer screening: A systematic review and meta-analysis.
    Dolatkhah R; Dastgiri S; Jafarabadi MA; Abdolahi HM; Somi MH
    Gastroenterol Hepatol; 2022 Dec; 45(10):753-766. PubMed ID: 35101601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Referral Rates for Genetic Assessment of Patients With Multiple Adenomas in United Kingdom Bowel Cancer Screening Programs.
    Alexander JL; Johnston BJ; Smith TJ; Yong KK; Marshall SM; Fawkes JDC; Martin JP; Seward EW; Saunders B; Monahan KJ
    Dis Colon Rectum; 2021 Sep; 64(9):1058-1063. PubMed ID: 34039904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
    Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
    Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.
    Rex DK; Boland CR; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Levin TR; Lieberman D; Robertson DJ
    Gastroenterology; 2017 Jul; 153(1):307-323. PubMed ID: 28600072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening.
    Johnson DH; Kisiel JB; Burger KN; Mahoney DW; Devens ME; Ahlquist DA; Sweetser S
    Gastrointest Endosc; 2017 Mar; 85(3):657-665.e1. PubMed ID: 27884518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multitarget stool DNA testing for colorectal-cancer screening.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM
    N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
    N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.
    Hundt S; Haug U; Brenner H
    Ann Intern Med; 2009 Feb; 150(3):162-9. PubMed ID: 19189905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
    Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study.
    Bosch LJW; de Wit M; Pham TV; Coupé VMH; Hiemstra AC; Piersma SR; Oudgenoeg G; Scheffer GL; Mongera S; Sive Droste JT; Oort FA; van Turenhout ST; Larbi IB; Louwagie J; van Criekinge W; van der Hulst RWM; Mulder CJJ; Carvalho B; Fijneman RJA; Jimenez CR; Meijer GA
    Ann Intern Med; 2017 Dec; 167(12):855-866. PubMed ID: 29159365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay.
    Zou H; Taylor WR; Harrington JJ; Hussain FT; Cao X; Loprinzi CL; Levine TR; Rex DK; Ahnen D; Knigge KL; Lance P; Jiang X; Smith DI; Ahlquist DA
    Gastroenterology; 2009 Feb; 136(2):459-70. PubMed ID: 19026650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent detection rates of fecal immunochemical test and questionnaire-based risk assessment for detecting proximal and distal advanced colorectal adenomas.
    Chen HD; Lu M; Zhang YH; Dai M
    Chin Med J (Engl); 2021 Jan; 134(5):605-607. PubMed ID: 33410637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.